Latest news with #BIOInternationalConvention
Business Wire
13 hours ago
- Business
- Business Wire
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced that members of its executive leadership team will be attending and participating in the upcoming BIO International Convention 2025, taking place June 16-19, 2025 in Boston. Cadrenal executives will participate in one-on-one meetings with investors and potential partners to provide key updates on the Company's strategic direction and clinical development of its lead asset, tecarfarin. Those interested in meeting with Cadrenal management should request a meeting through the Conference meeting portal or contact Investor Relations at cadrenal@ The BIO International Convention is the world's largest and most comprehensive biotechnology event, convening over 20,000 industry leaders from across the global life sciences ecosystem. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal's lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for a number of indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin and capture value in a market with high demand for safer, more manageable treatment options. Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit and connect with us on LinkedIn.
Yahoo
a day ago
- Business
- Yahoo
RESTEM to Present at the 2025 BIO International Convention
MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that Andres Isaias, its Chief Executive Officer, will present at the upcoming 2025 BIO International Convention taking place in Boston, MA from June 16 – 19, 2025. BIO International Convention Format: Corporate presentation and one-on-one meetings Presentation Date and Time: June 18, 2025, at 1:45 PM in Room 153A Location: Boston Convention & Exhibition Center, Boston, MA To register for the conference and schedule a one-on-one meeting with RESTEM's management, please visit About RESTEM RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies designed to modulate the immune system. Leveraging our proprietary products, robust clinical development expertise, and cutting-edge-manufacturing capabilities, we advance two potentially groundbreaking programs, Restem-L, our umbilical cord lining stem cells (ULSCs) program for auto-immune diseases and our natural killer cell (NK) therapeutics targeting senescence and age-associated disorders. Our therapies are intended to treat a broad range of disabling diseases and are designed to improve patient outcomes, as well as overall health and wellness. RESTEM is headquartered in Miami, Florida. For more information, please visit and follow us on X and LinkedIn. Investor Contact Daniel Ferry LifeSci Advisors +1.617.430.7576 daniel@ Media Contact Nelson CabautanRestem Group, Inc. +1.800.490.0924 ncabatuan@ in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Genprex to Participate at BIO 2025 International Convention
AUSTIN, Texas, June 3, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and participating at the BIO 2025 International Convention taking place June 16-19, 2025 in Boston, Mass. In attendance from Genprex's executive leadership team will be Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. Throughout the duration of the conference, Mr. Gallagher will be available in-person to conduct one-on-one meetings with industry groups to provide an overview of the Company's gene therapies for cancer and diabetes. For those interested in meeting with Mr. Gallagher or other members of Genprex's management team, please request a meeting through the conference meeting portal or by contacting Investor Relations at investors@ The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. About Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn. Cautionary Language Concerning Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2024. Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc.(877) 774-GNPX (4679) GNPX Investor Relationsinvestors@ GNPX Media ContactKalyn Dabbsmedia@ View original content to download multimedia: SOURCE Genprex, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
3 days ago
- Business
- Associated Press
NanoViricides (NNVC) to Unveil ‘Escape-Proof' Antiviral Platform at Major Biotech Convention
NV-387 was found to be highly effective against the 'tripledemic' respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs. NanoViricides (NNVC) is presenting at the prestigious BIO International Convention on June 16th, showcasing their revolutionary broad-spectrum antiviral platform that could transform how we treat viral infections—potentially creating the first 'empiric antiviral therapy' similar to how antibiotics work for bacterial infections. A Major Platform for a Breakthrough Company NanoViricides, Inc. (NYSE American: NNVC) has announced it will be presenting on Monday, June 16th, at 2:30pm at the BIO International Convention 2025 in Boston, MA. This isn't just any conference—the BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. Event Details: When: Monday, June 16, 2025 at 2:30 PM Where: Room 153B, Boston Convention and Exhibition Center Presenter: Dr. Anil R. Diwan, PhD, President and Executive Chairman The Revolutionary Science Behind NNVC What makes NanoViricides particularly compelling is their unique approach to antiviral therapy. NV-387 is a revolutionary broad-spectrum drug candidate designed to mimic host-side features that the virus particle uses as the first landing site in order to mount a cellular infection. The implications are staggering: an estimated 90-95% of human pathogens utilize the same common landing feature that is mimicked by NV-387, giving the drug its extremely broad antiviral spectrum. Why This Matters: The 'Escape-Proof' Advantage Traditional antivirals face a critical weakness—viruses mutate and develop resistance. NNVC's approach is fundamentally different. The virus cannot escape NV-387 even as it changes in the field, because the virus continues to use the sulfated proteoglycan features for attachment despite all changes. This represents a paradigm shift from existing vaccines, antibodies, and small chemical anti-viral modalities that are all readily defeated by viruses by relatively small changes, often in single viral proteins. Game-Changing Clinical Results The company's lead drug candidate has already demonstrated remarkable efficacy. NV-387 was found to be highly effective against the 'tripledemic' respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs. The Path to 'Empiric Antiviral Therapy' Perhaps most exciting is NNVC's vision for the future of antiviral treatment. NV-387 is expected to become an 'emperic therapy' for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections. NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy. This means doctors could prescribe antiviral treatment immediately upon seeing a patient with viral symptoms, without waiting for specific test results—a breakthrough that could save countless lives. Diverse Pipeline with Massive Market Potential NNVC isn't a one-trick pony. Their pipeline includes: NV-387: Targeting MPOX, moving toward Phase II trials in response to WHO's Public Health Emergency NV-HHV-1: A pan-herpesvirus drug candidate active against HSV-1, HSV-2, VZV, and potentially CMV, HHV-6, and HHV-8 NV-HIV-1: Showing strong efficacy in HIV infection models The overall market size of NV-387 indications is estimated to be well in excess of $10 billion. Beyond Antivirals: Platform Technology Opportunities The company's nanoviricide platform extends beyond just antiviral applications. The technology enables: Drug Rescue: Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work Oral Drug Delivery: Including for peptides like GLP-1 obesity drugs Targeted Delivery: Zip-code-specific delivery to tissues, cells, or pathogens What to Watch at BIO Convention Dr. Diwan will be providing updates on the company's drug pipeline and discussing platform technologies available for licensing. Dr. Diwan will also be available for meetings in the BIO Partnering™ match-making platform during the Convention from June 16th through June 19th, 2025. This presents significant partnership and licensing opportunities, potentially accelerating development timelines and providing non-dilutive funding sources. The Bottom Line NanoViricides represents a potentially transformative approach to antiviral therapy. Their presentation at BIO Convention offers a crucial opportunity to showcase their technology to potential partners and investors. With their lead drug candidate moving toward Phase II trials and a platform technology with applications beyond antivirals, NNVC could be positioned at the forefront of a new era in viral disease treatment. The June 16th presentation will be a key catalyst to watch, potentially providing insights into partnership opportunities, development timelines, and the company's strategic direction. For investors interested in revolutionary biotech plays, NNVC deserves serious consideration—while keeping in mind the inherent risks of clinical-stage pharmaceutical development. Some of the other biotech stocks to keep on radar include Vertex Pharmaceuticals (NASDAQ: VRTX), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Summit Therapeutics Inc. (NASDAQ: SMMT) and Moderna, Inc. (NASDAQ: MRNA). Disclaimer: This analysis is for informational purposes only and should not be considered as investment advice. Always conduct your own research and consult with financial advisors before making investment decisions. Clinical-stage pharmaceutical companies carry significant risks, and there can be no assurance of successful drug development or regulatory approval. This blog post is for informational purposes only and does not constitute financial advice or an endorsement of COEP or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated one thousand five hundred dollars by a 3rd party EDM Media for content distribution services on NNVC for June 2nd, 2025. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like 'believes,' 'anticipates,' 'estimates,' 'expects,' 'projects,' 'intends,' or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person's use of or access to this content. This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions. Source: Media Contact Company Name: UsaStockReport Contact Person: Ash K Email: [email protected] City: Frisco State: Texas Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: NanoViricides (NNVC) to Unveil 'Escape-Proof' Antiviral Platform at Major Biotech Convention
Globe and Mail
3 days ago
- Business
- Globe and Mail
NanoViricides (NNVC) to Unveil ‘Escape-Proof' Antiviral Platform at Major Biotech Convention
NV-387 was found to be highly effective against the "tripledemic" respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs. NanoViricides (NNVC) is presenting at the prestigious BIO International Convention on June 16th, showcasing their revolutionary broad-spectrum antiviral platform that could transform how we treat viral infections—potentially creating the first "empiric antiviral therapy" similar to how antibiotics work for bacterial infections. A Major Platform for a Breakthrough Company NanoViricides, Inc. (NYSE American: NNVC) has announced it will be presenting on Monday, June 16th, at 2:30pm at the BIO International Convention 2025 in Boston, MA. This isn't just any conference—the BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. Event Details: The Revolutionary Science Behind NNVC What makes NanoViricides particularly compelling is their unique approach to antiviral therapy. NV-387 is a revolutionary broad-spectrum drug candidate designed to mimic host-side features that the virus particle uses as the first landing site in order to mount a cellular infection. The implications are staggering: an estimated 90-95% of human pathogens utilize the same common landing feature that is mimicked by NV-387, giving the drug its extremely broad antiviral spectrum. Why This Matters: The "Escape-Proof" Advantage Traditional antivirals face a critical weakness—viruses mutate and develop resistance. NNVC's approach is fundamentally different. The virus cannot escape NV-387 even as it changes in the field, because the virus continues to use the sulfated proteoglycan features for attachment despite all changes. This represents a paradigm shift from existing vaccines, antibodies, and small chemical anti-viral modalities that are all readily defeated by viruses by relatively small changes, often in single viral proteins. Game-Changing Clinical Results The company's lead drug candidate has already demonstrated remarkable efficacy. NV-387 was found to be highly effective against the "tripledemic" respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs. The Path to "Empiric Antiviral Therapy" Perhaps most exciting is NNVC's vision for the future of antiviral treatment. NV-387 is expected to become an "emperic therapy" for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections. NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy. This means doctors could prescribe antiviral treatment immediately upon seeing a patient with viral symptoms, without waiting for specific test results—a breakthrough that could save countless lives. Diverse Pipeline with Massive Market Potential NNVC isn't a one-trick pony. Their pipeline includes: The overall market size of NV-387 indications is estimated to be well in excess of $10 billion. Beyond Antivirals: Platform Technology Opportunities The company's nanoviricide platform extends beyond just antiviral applications. The technology enables: What to Watch at BIO Convention Dr. Diwan will be providing updates on the company's drug pipeline and discussing platform technologies available for licensing. Dr. Diwan will also be available for meetings in the BIO Partnering™ match-making platform during the Convention from June 16th through June 19th, 2025. This presents significant partnership and licensing opportunities, potentially accelerating development timelines and providing non-dilutive funding sources. The Bottom Line NanoViricides represents a potentially transformative approach to antiviral therapy. Their presentation at BIO Convention offers a crucial opportunity to showcase their technology to potential partners and investors. With their lead drug candidate moving toward Phase II trials and a platform technology with applications beyond antivirals, NNVC could be positioned at the forefront of a new era in viral disease treatment. The June 16th presentation will be a key catalyst to watch, potentially providing insights into partnership opportunities, development timelines, and the company's strategic direction. For investors interested in revolutionary biotech plays, NNVC deserves serious consideration—while keeping in mind the inherent risks of clinical-stage pharmaceutical development. Some of the other biotech stocks to keep on radar include Vertex Pharmaceuticals (NASDAQ: VRTX), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Summit Therapeutics Inc. (NASDAQ: SMMT) and Moderna, Inc. (NASDAQ: MRNA). Disclaimer: This analysis is for informational purposes only and should not be considered as investment advice. Always conduct your own research and consult with financial advisors before making investment decisions. Clinical-stage pharmaceutical companies carry significant risks, and there can be no assurance of successful drug development or regulatory approval. This blog post is for informational purposes only and does not constitute financial advice or an endorsement of COEP or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated one thousand five hundred dollars by a 3rd party EDM Media for content distribution services on NNVC for June 2nd, 2025. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like 'believes,' 'anticipates,' 'estimates,' 'expects,' 'projects,' 'intends,' or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person's use of or access to this content. This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions. Source: Media Contact Company Name: UsaStockReport Contact Person: Ash K Email: editor@ City: Frisco State: Texas Country: United States Website:
